HIV/AIDS: Recent Advances in Antiretroviral Agents

被引：11

作者：

Nikolopoulos, Georgios ^{[2
]}

Bonovas, Stefanos ^{[1
,3
]}

Tsantes, Argirios ^{[4
,5
]}

Sitaras, Nikolaos M. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Pharmacol, Athens 11527, Greece

[2] Ctr Dis Control & Prevent, HIV Infect Off, Athens, Greece

[3] Ctr Dis Control & Prevent, Dept Epidemiol Surveillance & Intervent, Athens, Greece

[4] Univ Athens, Sch Med, Attikon Gen Hosp, Haematol Lab, GR-10679 Athens, Greece

[5] Univ Athens, Sch Med, Attikon Gen Hosp, Blood Bank Unit, GR-10679 Athens, Greece

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2009年 / 9卷 / 08期

关键词：

HIV; antiretrovirals; CCR5; integrase inhibitors; maturation inhibitors; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1; REVERSE-TRANSCRIPTASE; MATURATION INHIBITOR PA-457; PLACEBO-CONTROLLED TRIAL; SMALL-MOLECULE INHIBITOR; CD4(+) T-CELLS; IN-VITRO; INTEGRASE INHIBITOR; INFECTED PATIENTS; MONOCLONAL-ANTIBODY;

D O I：

10.2174/138955709788681609

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Despite the considerable progress in antiretroviral therapy, the eradication of HIV-1 remains unfeasible. Therefore, novel agents are under investigation. The aim of this review is to summarize the conventional compounds, to describe the recently approved agents, and to take a comprehensive look at the clinically relevant findings of current research.

引用

页码：900 / 910

页数：11

共 95 条

[1] In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat) [J].

Adamson, Catherine S. ;

Ablan, Sherimay D. ;

Boeras, Ioana ;

Goila-Gaur, Ritu ;

Soheilian, Ferri ;

Nagashima, Kunio ;

Li, Feng ;

Salzwedel, Karl ;

Sakalian, Michael ;

Wild, Carl T. ;

Freed, Eric O. .

JOURNAL OF VIROLOGY, 2006, 80 (22) :10957-10971

[2] A New Generation of Peptide-based Inhibitors Targeting HIV-1 Reverse Transcriptase Conformational Flexibility [J].

Agopian, Audrey ;

Gros, Edwige ;

Aldrian-Herrada, Gudrun ;

Bosquet, Nathalie ;

Clayette, Pascal ;

Divita, Gilles .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (01) :254-264

[3] TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 [J].

Andries, K ;

Azijn, H ;

Thielemans, T ;

Ludovici, D ;

Kukla, M ;

Heeres, J ;

Janssen, P ;

De Corte, B ;

Vingerhoets, J ;

Pauwels, R ;

de Béthune, MP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4680-4686

[4] Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection [J].

Anker, Mary ;

Corales, Roberto B. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (01) :97-103

[5]

[Anonymous], 2008, AIDS Patient Care STDS, V22, P159

[6]

[Anonymous], 2008, Physical activity guidelines for Americans, P1

[7] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].

Baba, M ;

Nishimura, O ;

Kanzaki, N ;

Okamoto, M ;

Sawada, H ;

Iizawa, Y ;

Shiraishi, M ;

Aramaki, Y ;

Okonogi, K ;

Ogawa, Y ;

Meguro, K ;

Fujino, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703

[8] Recent status of HIV-1 gene expression inhibitors [J].

Baba, Masanori .

ANTIVIRAL RESEARCH, 2006, 71 (2-3) :301-306

[9] Inhibition of HIV entry by carbohydrate-binding proteins [J].

Balzarini, J. .

ANTIVIRAL RESEARCH, 2006, 71 (2-3) :237-247

[10] HIV-1 TAR RNA: The target of molecular interactions between the virus and its host [J].

Bannwarth, S ;

Gatignol, A .

CURRENT HIV RESEARCH, 2005, 3 (01) :61-71

← 1 2 3 4 5 6 7 8 9 10 →